Ignite Creation Date:
2025-12-25 @ 4:25 AM
Ignite Modification Date:
2026-03-10 @ 4:38 AM
Study NCT ID:
NCT00611520
Status:
COMPLETED
Last Update Posted:
2011-01-28
First Post:
2008-01-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Symbicort in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Organization:
Study Overview
Official Title:
Symbicort in Chronic Obstructive Pulmonary Disease
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SYMBOL
Brief Summary:
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. pneumologists and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: